U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07419347) titled 'Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data' on Feb. 12.
Brief Summary: The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Study Start Date: Feb. 23
Study Type: OBSERVATIONAL
Condition:
Hepatitis C Virus (HCV)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AbbVie
Published by HT Digital Content Services with permission from Health Daily Digest....